Table 2.
Patients were followed up for the efficacy and toxicity of the combination therapy
| Cases | Baseline EGFR mutation | Previous treatment | Mutation profile at resistance to osimertinib | Treatment | Initial dose | Dose adjustment | Best overall response | Progression-free time | Adverse effect (grade) |
|---|---|---|---|---|---|---|---|---|---|
| 66 male | EGFR L858R | Gefitinib→chemo→Osimertinib | EGFR L858R BRAF V600E |
D + T + O | D:150 mg bid T:2 mg qd O:80 mg qd |
D:75 mg bid T:2 mg qd O:80 mg qod |
PR | >13months | Pyrexia(G2) Rash(G1) Fatigue(G1) Nausea(G1) |
| 56 female | EGFR 19del | Gefitinib→Osimertinib | EGFR T790M BRAF V600E |
D + T + O | D:150 mg bid T:2 mg qd O:80 mg qd |
D:100 mg bid T:1 mg qd O:80 mg qod |
SD | 6 months | Fatigue(G2) Pain(G2) |
| 79 female | EGFR T790M | Osimertinib→ Chemo+ICI |
EGFR L858R BRAF V600E |
D + T + O | D:75 mg bid T:2 mg qd O:80 mg qod |
Not need | - | 1 month | Fatigue(G2) Pain(G3) Nausea(G1) |
| 61 male | EGFR 19del | Osimertinib | EGFR L858R BRAF V600E |
D + T + O | D:150 mg bid T:2 mg qd O:80 mg qd |
Not need | PR | >5 months | Rash(G1) Fatugue(G1) |
| 77 female | EGFR 19del | Gefitinib→Osimertinib | EGFR L858R BRAF V600E |
D + T + O | D:100 mg bid T:2 mg qd O:80 mg qd |
D:75 mg bid T:2 mg qd O:80 mg qod |
PR | 18 months | Pyrexia(G2) decreased appetite(G2) Fatigue(G2) |
| 67 female | EGFR L858R |
Gefitinib→Osimertinib | EGFR L858R BRAF V600E |
D + T + O | D:100 mg bid T:2 mg qd O:80 mg qd |
Not need | PR | 14 months | Diarrhea(G1) Rash(G1) Fatigue(G1) |
| 68 female | EGFR L858R |
Osimertinib | EGFR L858R BRAF V600E |
D + T + O | D:150 mg bid T:2 mg qd O:80 mg qd |
D:75 mg bid T:2 mg qd O:80 mg qod |
PR | 20 months | Pyrexia(G2) decreased appetite(G1) Rash(G1) |
This table presents data related to patient follow-up during a combination therapy study. It includes information on the effectiveness of the combination therapy in terms of its efficacy (how well it achieved the desired treatment outcomes) and any observed toxicity (side effects or adverse reactions) experienced by the patients during the follow-up period. The table provides valuable insights into the performance and safety of the combination therapy in a clinical setting.
Efficacy and treatment toxicity of our hospital patients with osimertinib-induced BRAFV600 mutations.
D, dabrafenib; O, osimertinib; T, trametinib.